Comparison of safety of lecanemab and donanemab: a real-world disproportionality analysis using the FDA adverse event reporting system
BackgroundLecanemab and donanemab are anti-amyloid-β (Aβ) monoclonal antibodies recently approved for the treatment of Alzheimer’s disease (AD). Although both agents have demonstrated therapeutic potential, their post-marketing adverse event reporting profiles remain insufficiently characterized and...
Guardado en:
| Autores principales: | , , , , , |
|---|---|
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Frontiers Media S.A.
2026-06-01
|
| Colección: | Frontiers in Pharmacology |
| Materias: | |
| Acceso en línea: | https://www.frontiersin.org/articles/10.3389/fphar.2026.1868789/full |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|